Takeda Reports Zasocitinib Achieves High Psoriasis Clearance
Takeda announced Phase 3 results for zasocitinib (TAK-279) at the 2026 AAD meeting showing about 69–71% of patients achieved clear or almost clear skin (sPGA 0/1) at week 16 and significant PASI 75/90/100 improvements versus placebo and apremilast. Safety was consistent with Phase 2b with no new signals, responses deepened through week 24 and remained durable to week 60; Takeda plans NDA submissions starting fiscal 2026.
Scoring Rationale
Strong, well-powered Phase 3 efficacy with official AAD presentation; limited by clinical focus outside core data-science topics.
Practice interview problems based on real data
1,500+ SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problemsStep-by-step roadmaps from zero to job-ready — curated courses, salary data, and the exact learning order that gets you hired.
Sources
- Read OriginalTakeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Caremontrealgazette.com
